Gilead (GILD) CCO Johanna Mercier Sells 28,000 Shares Under 10b5-1 Plan
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025.
Rhea-AI Filing Summary
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.
Positive
- Transactions executed under a Rule 10b5-1 trading plan, indicating pre-established compliance documentation
- Vesting schedule disclosed for the non-qualified stock options (four-year schedule; 25% at first anniversary, remainder quarterly)
Negative
- Insider sold 28,000 shares on 08/15/2025 at prices roughly between $117.91 and $119.01, reducing reported beneficial ownership to as low as 114,168 shares
Insights
TL;DR: Insider executed option acquisitions and sold 28,000 shares under a 10b5-1 plan; transactions appear routine and disclosed.
The Form 4 reports coordinated exercises/acquisitions of non-qualified stock options at a $66.64 strike and contemporaneous open-market sales executed under a Rule 10b5-1 plan adopted Feb 20, 2025. Aggregate sales reported on 08/15/2025 total 28,000 shares at prices in the ~$117.91–$119.01 range, which generated material cash proceeds relative to a single-person insider but are not, by themselves, a company-level event. The filing also documents remaining equity and option holdings (common shares and options shown at various post-transaction balances, e.g., 114,168 shares beneficially owned). For investors, these are governance/compliance disclosures rather than operating or financial performance signals.
TL;DR: Transactions executed under a documented 10b5-1 plan with full vesting schedule disclosure — consistent with standard insider liquidity practices.
The Form 4 clearly states the trades were made pursuant to a Rule 10b5-1 trading plan, which provides an affirmative defense to insider trading allegations when properly adopted and followed. The filing includes the vesting schedule for the options (four-year schedule, 25% at year one, remainder quarterly at 6.25%), and provides ranges for sale prices with an offer to supply detailed trade-by-trade pricing on request. Documentation and disclosure appear complete for regulatory compliance; no additional governance issues are identified within the filing itself.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified Stock Option (Right to Buy) | 11,800 | $0.00 | $0.00 |
| Exercise | Non-qualified Stock Option (Right to Buy) | 700 | $0.00 | $0.00 |
| Exercise | Non-qualified Stock Option (Right to Buy) | 11,800 | $0.00 | $0.00 |
| Exercise | Non-qualified Stock Option (Right to Buy) | 700 | $0.00 | $0.00 |
| Exercise | Common Stock | 11,800 | $66.64 | $786K |
| Sale | Common Stock | 11,800 | $118.5044 | $1.40M |
| Exercise | Common Stock | 700 | $66.64 | $47K |
| Sale | Common Stock | 700 | $118.9686 | $83K |
| Exercise | Common Stock | 11,800 | $66.64 | $786K |
| Sale | Common Stock | 11,800 | $118.5089 | $1.40M |
| Exercise | Common Stock | 700 | $66.64 | $47K |
| Sale | Common Stock | 700 | $118.9686 | $83K |
| Sale | Common Stock | 2,800 | $118.5074 | $332K |
| Sale | Common Stock | 200 | $118.965 | $24K |
Footnotes (6)
- F1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
- F2. Sales prices for the transactions reported here range from $117.91 to $118.89. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F3. Sales prices for the transactions reported here range from $118.91 to $119.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or the shareowners upon request.
- F4. Sales prices for the transactions reported here range from $117.91 to $118.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F5. Sales prices for the transactions reported here range from $118.95 to $118.98. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F6. The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Johanna Mercier (GILD) report on Form 4 for 08/15/2025?
Were the transactions made under a 10b5-1 plan for GILD insider trades?
What is the vesting schedule for the reported options in the Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.